checkAd
    Startseite > Aktien > Alpha Cognition > Nachrichten
    Alpha Cognition Aktie
    0,5040
     
    USD
    +0,80 %
    +0,0040 USD
    Letzter Kurs 16:54:29 Nasdaq OTC
    ISIN: CA02074J2048 · WKN: A3CNL7 · SYM: ACOGF · Kanada

    Neueste Nachrichten

    Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
    04.04.24 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12: 00pm EDT.
    20.03.24 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
    22.02.24 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Provides Business Update
    12.02.24 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
    19.01.24 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
    22.12.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
    07.12.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
    05.12.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
    28.11.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
    08.11.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
    16.10.23 · Business Wire (engl.) · Alpha Cognition
    Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
    27.09.23 · Business Wire (engl.) · Alpha Cognition